Inicio>>Signaling Pathways>> DNA Damage/DNA Repair>> HDAC>>J22352

J22352

Catalog No.GC34629

J22352 es un inhibidor de HDAC6 altamente selectivo y similar a PROTAC (proteolysis-targetingchimeras) con un valor IC50 de 4,7 nM. J22352 promueve la degradaciÓn de HDAC6 e induce efectos anticancerÍgenos al inhibir la autofagia y provocar la respuesta inmunitaria antitumoral en los cÁnceres de glioblastoma, y conduce a la restauraciÓn de la actividad antitumoral del huésped al reducir la actividad inmunosupresora de PD-L1.

Products are for research use only. Not for human use. We do not sell to patients.

J22352 Chemical Structure

Cas No.: 2252395-44-9

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
119,00 $
Disponible
5mg
108,00 $
Disponible
10mg
171,00 $
Disponible
50mg
495,00 $
Disponible
100mg
846,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

J22352 is a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM. J22352 promotes HDAC6 degradation and induces anticancer effects by inhibiting autophagy and eliciting the antitumor immune response in glioblastoma cancers, and leading to the restoration of host antitumor activity by reducing the immunosuppressive activity of PD-L1[1]. HDAC6|4.7 nM (IC50)

J22352 (0.1-20 μM; 72 hours) decreases U87MG cell viability in a dose-dependent manner[1]. J22352 (10 μM; 24 hours) shows a dose-dependent decrease in HDAC6 protein abundance[1]. Cell Viability Assay[1] Cell Line: U87MG cells

J22352 (10mg/kg; given i.p. per day for 14 days in male nude mice) results in a >80% tumor growth inhibition (TGI) rate. J22352 is well tolerated in mice[1]. Animal Model: Male nude mice (BALB/cAnN.Cg-Foxnlnu/CrlNarl, 4-6 weeks old)[1]

[1]. Liu JR, et al. High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma. Biochem Pharmacol. 2019 May; 163:458-471.

Reseñas

Review for J22352

Average Rating: 5 ★★★★★ (Based on Reviews and 17 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for J22352

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.